EWTX on Nasdaq

Edgewise Therapeutics, Inc.

Our mission is to discover new medicines that improve the lives of people facing serious muscle disease.3 From its latest annual report

Price unavailable

Last updated Oct 19, 2026.

Overview

Compare with another stock.

  • TickerEWTX on Nasdaq1
  • IndustryPharmaceutical Preparations1
  • HeadquartersBoulder, Colorado1
  • Incorporated inDE2
  • Business address1715 38Th St, Boulder, Co 803012
  • Filer categoryLarge accelerated filer2

See how the biggest companies compare on our leaderboards

Our mission is to discover new medicines that improve the lives of people facing serious muscle disease.3 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Financial statements

Operating income4567-$191.4M in 2025+1013% since 2020
-$200.0M-$150.0M-$100.0M-$50.0M02020: -$17.2M-$17.2M20202021: -$43.2M-$43.2M2021+151%2022: -$71.7M-$71.7M2022+66%2023: -$114.4M-$114.4M2023+60%2024: -$158.8M-$158.8M2024+39%2025: -$191.4M-$191.4M2025+21%
Net income4567-$167.8M in 2025+880% since 2020
-$200.0M-$150.0M-$100.0M-$50.0M02020: -$17.1M-$17.1M20202021: -$42.8M-$42.8M2021+150%2022: -$67.6M-$67.6M2022+58%2023: -$100.2M-$100.2M2023+48%2024: -$133.8M-$133.8M2024+34%2025: -$167.8M-$167.8M2025+25%

Every line of the income statement as filed: the last 3 fiscal years, latest first.7

Period ending2025-12-312024-12-312023-12-31
Research and development$151.4M$127.0M$90.9M
General and administrative$40.0M$31.9M$23.5M
Total operating expenses$191.4M$158.8M$114.4M
Loss from operations-$191.4M-$158.8M-$114.4M
Interest income$23.6M$25.0M$14.2M
Total other income$23.6M$25.0M$14.2M
Net loss-$167.8M-$133.8M-$100.2M
Unrealized gain on available-for-sale securities$257.0K$321.0K$1.5M
Total comprehensive loss-$167.5M-$133.5M-$98.7M
Net loss per share, basic (in dollars per share)-$1.63-$1.45-$1.57
Net loss per share, diluted (in dollars per share)-$1.63-$1.45-$1.57
Weighted-average shares outstanding, basic (in shares)102.9M shares92.4M shares63.7M shares
Weighted-average shares outstanding, diluted (in shares)102.9M shares92.4M shares63.7M shares

Compare Edgewise Therapeutics, Inc. with another company

Leadership

Who has led Edgewise Therapeutics, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Kevin Koch2021–now

President

  1. Kevin Koch2021–now

Chief financial officer

  1. Michael Nofi2025–now
2025
Board members and other officers (15)

Timeline

  1. Mar 25, 2021New chief executive Kevin Koch becomes CEO11

Filings

356 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 47 major events, 170 insider forms, 57 large holders, 62 other. The latest 20:

  1. Oct 2, 20264 PRIMARY DOCUMENT EDGAR
  2. Aug 17, 20264/A PRIMARY DOCUMENT EDGAR
  3. Aug 17, 20264/A PRIMARY DOCUMENT EDGAR
  4. Aug 17, 20264/A PRIMARY DOCUMENT EDGAR
  5. Aug 17, 20264/A PRIMARY DOCUMENT EDGAR
  6. Aug 17, 20264/A PRIMARY DOCUMENT EDGAR
  7. Aug 14, 20264 PRIMARY DOCUMENT EDGAR
  8. Aug 14, 20264 PRIMARY DOCUMENT EDGAR
  9. Aug 14, 20264 PRIMARY DOCUMENT EDGAR
  10. Aug 14, 20264 PRIMARY DOCUMENT EDGAR
  11. Aug 14, 2026SCHEDULE 13G/A EDGAR
  12. Aug 14, 20264 PRIMARY DOCUMENT EDGAR
  13. Aug 14, 20264 PRIMARY DOCUMENT EDGAR
  14. Aug 14, 2026SCHEDULE 13G/A EDGAR
  15. Aug 14, 2026SCHEDULE 13G/A EDGAR
  16. Aug 13, 2026144 EDGAR
  17. Aug 6, 20268-K EDGAR
  18. Aug 6, 202610-Q EDGAR
  19. Aug 6, 2026SCHEDULE 13G EDGAR
  20. Jul 17, 20264 PRIMARY DOCUMENT EDGAR

The 356 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

113 open-market trades by officers, directors and large owners since October 2021: 11 buys and 102 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Aug 13, 2026Donovan Joanne M.CMOSale2,919$43.41$126.7KForm 4
Aug 12, 2026Russell Alan JChief Scientific OfficerSale5,901$43.73$258.1KForm 4
Aug 12, 2026Derakhshan BehradChief Business OfficerSale5,100$43.81$223.4KForm 4
Aug 12, 2026Donovan Joanne M.CMOSale6,522$43.85$286.0KForm 4
Aug 12, 2026MOORE JOHN RGeneral CounselSale5,016$43.83$219.8KForm 4
Aug 12, 2026KOCH KEVINPresident and CEOSale17,971$43.68$785.0KForm 4
Jul 1, 2026Russell Alan JChief Scientific OfficerSale200,000$39.41$7.9MForm 4
May 5, 2026Donovan Joanne M.CMOSale50,000$38.57$1.9MForm 4
May 4, 2026Donovan Joanne M.CMOSale5,230$31.29$163.6KForm 4
Apr 1, 2026Donovan Joanne M.CMOSale28,662$32.31$926.1KForm 4
Mar 31, 2026Donovan Joanne M.CMOSale21,338$32.12$685.4KForm 4
Mar 27, 2026Donovan Joanne M.CMOSale16,358$30.98$506.8KForm 4
Jan 21, 2026Edris BadreddinDirectorSale115,471$29.44$3.4MForm 4
Nov 12, 2025Russell Alan JChief Scientific OfficerSale100,000$21.12$2.1MForm 4
Nov 11, 2025Fox Jonathan CDirectorBuy10,700$18.64$199.4KForm 4
Aug 26, 2025Russell Alan JChief Scientific OfficerSale100,000$14.60$1.5MForm 4
Aug 12, 2025MOORE JOHN RGeneral CounselSale2,098$13.39$28.1KForm 4
Aug 12, 2025Derakhshan BehradChief Business OfficerSale2,491$13.39$33.4KForm 4
Aug 12, 2025Carruthers R MichaelChief Financial OfficerSale1,428$13.39$19.1KForm 4
Aug 12, 2025Russell Alan JChief Scientific OfficerSale1,907$13.39$25.5KForm 4

All 113 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Orbimed Advisors LLC15,518,492$630.5M12.0%No change
Paradigm Biocapital Advisors LP10,215,455$415.1M7.8%+2,850,417
Ra Capital Management, L.P.8,392,730$341.0M3.0%−2,035,707
BlackRock, Inc.6,606,336$268.4M0.0%+133,345
Jupiter Topco LLC6,075,331$246.9M0.1%New
Fmr LLC5,489,135$223.0M0.0%+4,472,083
Novo Holdings A/s5,350,000$217.4M12.6%No change
Driehaus Capital Management LLC4,728,623$192.1M1.1%+250,681
Perceptive Advisors LLC4,373,974$177.7M2.8%−50,000
Vanguard Capital Management LLC3,860,670$156.9M0.0%+72,509
Baker Bros. Advisors LP3,701,719$150.4M0.8%−2,874,221
Siren, L.L.C.3,184,629$129.4M2.6%−1,245,634
Cormorant Asset Management, LP2,510,000$102.0M5.2%−750,000
Geode Capital Management, LLC2,174,051$88.3M0.0%+384,232
Integral Health Asset Management, LLC2,000,000$81.3M3.3%+400,000
Braidwell LP1,996,965$81.1M3.1%−350,618
Morgan Stanley1,948,597$79.2M0.0%−297,431
State Street Corp1,827,927$74.3M0.0%+111,104
Alliancebernstein L.P.2,119,024$66.7M0.0%+396,855
Mpm Bioimpact LLC1,620,780$65.9M4.0%−39,916
Bank Of America Corp /de/1,558,260$63.3M0.0%+230,900
Qube Research & Technologies Ltd1,252,507$50.9M0.1%+426,597
Dimensional Fund Advisors LP1,139,726$46.3M0.0%−79,991
American Century Companies Inc1,127,078$45.8M0.0%−20,098
First Light Asset Management, LLC1,095,171$44.5M2.7%+93,325

13F reports cover disclosed long positions in U.S. stocks only.

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41